Monica Mita, M.D., professor of hematology and medical oncology at CTRC, is co-director of the course for cancer care providers.
Printer Friendly Format

Physicians, nurses and pharmacists are faced with a dizzying array of new drugs to consider when treating their cancer patients. A San Antonio conference March 19-20 about newly approved anticancer agents is intended to help clinicians address a variety of practical issues, such as treating early- and late- stage disease, using treatments in combination and managing side effects.

The meeting, “Practical Applications of New Agents in Oncology™,” will bring together scientists from renowned medical centers around the country including Memorial Sloan-Kettering in New York and the Cleveland Clinic in Ohio with faculty from the Cancer Therapy & Research Center (CTRC) at the UT Health Science Center San Antonio. Sponsor of the 12th annual meeting is the CTRC’s Institute for Drug Development, which has developed or tested at least 20 cancer drugs approved by the Food and Drug Administration (FDA) in recent years.

Related links: Program brochure Program agenda

“We believe cancer patients have better outcomes and better quality of life when their health care professionals have the chance to receive updated information from outstanding opinion leaders about drugs that have been recently approved or are about to be approved,” said Monica Mita, M.D., course co-director and assistant professor of hematology and medical oncology at CTRC.

"Speakers will emphasize the drugs’ mechanism of action, efficacy, side effects and treatment of side effects,” Dr. Mita added. “They also will talk about novel and promising drugs or pathways that could further change the way we practice. The face of modern oncology and hematology has changed tremendously in the last five to 10 years due to the development and approval of new drugs.”

Speakers will discuss several new agents to treat specific types of cancers or tumors: blood, breast, lung, gastrointestinal tract, kidney and sarcoma. Participants are invited to meet the experts over lunch.

Speakers represent renowned medical centers from around the country
Presenters include:

• Ronald Bukowski, M.D., Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio;
  
• Wendy Crabbe, RN, UT Health Science Center;
  
• Brad Frei, Pharm.D., University of the Incarnate Word;
  
• Robert Maki, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center, New York, N.Y.;
  
• Alain Mita, M.D., UT Health Science Center;
  
• Monica Mita, M.D., UT Health Science Center;
  
• Swaminathan Padmanabhan, M.D., UT Health Science Center;
  
• Ramesh Ramanathan, M.D., TGen Clinical Research Services, Scottsdale, Ariz.
  
• Peter Ravdin, M.D., Ph.D., UT Health Science Center;
  
• Alan Sandler, M.D., Oregon Health & Science University, Portland, Ore.;
  
• Scott Soefje, Pharm.D., BCOP, UT Health Science Center;
  
• Glen Weiss, M.D., The Translational Genomic Research Institute, Phoenix, Ariz.;
  
• Michelle Wright, RN, UT Health Science Center; and
  
• Stacey Young-McCaughan, RN, Ph.D., UT Health Science Center.

For more information or to register for the conference, to be held at the Omni San Antonio Hotel at the Colonnade, please visit www.newagents.org, or contact Marissa Howard, (210) 567-4435.

# # #